1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
659151561F5F8F34C85257CEB0073485C
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-ipad-utilization-in-managed-markets-security-and-measuring-effectiveness?OpenDocument
18
19OpenDocument
2018.97.9.169
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Market Access » Managed Care Organizations and Winning Practices

iPad Utilization in Managed Markets: Security and Measuring Effectiveness

ID: 5311


Features:

14 Info Graphics

17 Data Graphics

130+ Metrics


Pages/Slides: 38


Published: Pre-2020


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "iPad Utilization in Managed Markets: Security and Measuring Effectiveness"


STUDY OVERVIEW

Given the expanding role of technology and the increased usage of iPads by Managed Markets teams, it's critical for organizations to measure the effectiveness of these new devices and to ensure they are creating value for both the customer groups and the internal teams. Best Practices, LLC undertook this research to investigate the issues of security & assessing overall effectiveness for the iPad as a tool for Managed Markets teams.

The research is focused on valuable metrics surrounding security and compliance issues faced while using iPad and measuring the effectiveness of the iPad in a managed markets field setting. Executives can use this study to better evaluate their iPad strategy while ensuring their security procedures will protect confidential information.

These research findings provide industry metrics and insights that can serve as a reference point for managed markets leaders as they seek to deploy and improve the usage of iPads in their groups.

KEY TOPICS

  • Current State of iPad Deployment
  • Universe of Learning: Key Demographics of Participating Companies
  • iPad Security and Compliance
  • Field Usage and Measuring Effectiveness

SAMPLE KEY METRICS
  • Security procedure in place for misplaced or stolen iPads
  • Current security response trigger in the case of misplaced or lost iPad
  • Ability to remotely wipe iPad of all confidential information
  • Oversight of system security for iPads
  • Frequency in which electronic history is checked to ensure compliance
  • Departmental oversight of electronic histories
  • iPad field usage by Managed Market teams
  • Effectiveness of iPad for key field activities
  • KPI's measured to assess the effectiveness of the iPad as a sales tool
  • Estimated change in KPI performance since deploying an iPad
  • Barriers to access and utilization of iPads
  • Effectiveness of iPad presentation to a physician compared to a print material
  • Change in customer perception of call quality since deploying the iPad
  • Physician demographic most likely to be engaged during a rep visit which includes the use of iPads
  • Effectiveness impact of iPads on national account and trade show interactions
  • Current ROI status post iPad implementation

SAMPLE KEY FINDING
  • Impact on Managed Markets: Almost 3 out of 10 companies have implemented iPads for their Managed Markets teams. Around half of the partners noted a significant improvement in their interactions during national accounts and trade shows.
  • Realization of ROI: Seven of 10 participants have yet to see a demonstrable Return on Investment as a result of iPad deployment. The deployment tenure of those who have achieved some ROI averages around 18 months. Thus, it is still a bit too early to determine the degree of ROI for many companies, most of whom have just finished one cycle time of implementation.


METHODOLOGY

The research is based on the insights of 17 respondents from 14 leading global companies.  Almost half of respondents work as directors, senior directors or vice presidents. 

Industries Profiled:
Pharmaceutical; Biotech; Academic; Health Care; Electronics; Biopharmaceutical; Clinical Research; Laboratories; Chemical


Companies Profiled:
Janssen; Abbvie; Boehringer Ingelheim; Rimedio; Teva Pharmaceutical Industries Ltd; Abbott Nutrition; Lung LLC; Panasonic; Novo Nordisk; Biogen Idec; Sanofi; UCB Pharma; Astellas; Genentech

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.